Login to Your Account



Evotec Finds New Partner for NMDA Drugs in Janssen Deal

By Nuala Moran
Staff Writer

Wednesday, December 19, 2012
A year and a half after Roche AG handed back rights, Evotec AG has found a new home for its NMDA antagonist portfolio, in a licensing deal with Janssen Pharmaceuticals Inc. worth a potential $75 million up to launch.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription